Resultantly, the cardioprotective effects of the low-level activity of these enzymes (NADPH oxidase 4, iNOS, and eNOS) are converted by the metabolic syndrome milieu factors to a cardiovascular damaging status via an enzymatic interplay of self-sustaining high-level activity. The gene discussed is NOS3; the disease is metabolic syndrome.